Generic medicine substitution practices among community pharmacists: A nationwide study from Malaysia

被引：9
作者：
Chong C.P. [1 ]
Hassali M.A. [2 ]
Bahari M.B. [1 ]
Shafie A.A. [2 ]
机构：
[1] Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden
[2] Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden
来源：
Journal of Public Health | 2011年 / 19卷 / 1期
关键词：
Community pharmacist; Cost saving; Generic substitution; Patient; Physician;
D O I：
10.1007/s10389-010-0349-3
中图分类号：
学科分类号：
摘要：
Aims: This study aims to assess generic medicine substitution practices among Malaysian community pharmacists. Method: A cross-sectional nationwide descriptive study using a specific mailing data collection form was conducted from May 2007 through December 2007. A sample of 1,419 community pharmacies was involved in this study. Data were collected across the brand name medicine requests encountered on 14 working days and for which an equivalent generic product was available. Pharmacists' generic substitution rate, physicians' and patients' acceptance of substitution and cost saving achieved from substitution were assessed. Results: Responses were received from 157 pharmacies (response rate 11.1%). The pharmacists recommended generic substitution for 84.7% (1,538/1,815) of the brand name medicine requests. While suggesting substitution, the pharmacists voluntarily consulted the physicians for 13.1% (91/695) of the recommendations which involved prescription orders. The majority of the physicians (87.9%) when consulted by the pharmacists accepted the recommendation for substitution. Meanwhile, 88.9% (1,368/1,538) of the pharmacists' substitution suggestions were accepted by the patients. The overall patients' expenditure on medicines was reduced by a total of 57.4% (Malaysian ringgit 27,266.30 or US 7,369.30; US 1.00 = Malaysian ringgit 3.70) through acceptance of substitution. Conclusion: The Malaysian community pharmacists actively recommended generic substitution for brand name medicine requests which they encountered. Both the physicians and patients highly accepted the substitution recommendation and this contributed to significant reduction in patients' medicines expenditure. © 2010 Springer-Verlag.
引用
收藏
页码：81 / 90
页数：9
相关论文
共 37 条
[1]  
Allenet B., Barry H., Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: Survey of 1,000 French community pharmacists, Pharm World Sci, 25, pp. 197-202, (2003)
[2]  
Andersen M.L., Laursen K., Schaumann M., Et al., How do patients evaluate the newly introduced system of substituting prescriptions?, Ugeskr Laeger, 162, 45, pp. 6066-6069, (2000)
[3]  
Andersson K., Sonesson C., Petzold M., Et al., What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden, Pharmacoepidemiol Drug Saf, 14, pp. 341-348, (2005)
[4]  
Andersson K., Bergstrom G., Petzold M.G., Et al., Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals, Health Policy, 81, pp. 376-384, (2007)
[5]  
Consumer confidence in generic drug products down in wake of industry scandal, but satisfaction with products remains high, survey shows, Am J Hosp Pharm, 47, pp. 468-476, (1990)
[6]  
Babar Z.U.D., Awaisu A., Evaluating community pharmacists' perceptions and practices on generic medicines: A pilot study from Peninsular Malaysia, J Generic Med, 5, pp. 315-330, (2008)
[7]  
Banahan B., Kolassa E., Generic Substitution and Narrow Therapeutic Index Drugs: A National Survey of Retail and Hospital Pharmacies, (1994)
[8]  
Barrett L.L., Physicians' Attitudes and Practices Regarding Generic Drugs, (2005)
[9]  
Ess S.M., Schneeweiss S., Szucs T.D., European healthcare policies for controlling drug expenditure, Pharmacoeconomics, 21, pp. 89-103, (2003)
[10]  
Fischer M.A., Avorn J., Potential savings from increased use of generic drugs in the elderly: What the experience of Medicaid and other insurance programs means for a Medicare drug benefit, Pharmacoepidemiol Drug Saf, 13, pp. 207-214, (2004)
1234